Zacks Investment Research lowered shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a hold rating to a sell rating in a report published on Friday morning.

According to Zacks, “Teva is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Also, Teva’s shares have underperformed the generic industry in the past one year. Mylan’s earlier-than-expected launch of the first generic version of the 40-mg strength of Copaxone was a major setback for Teva. Though Teva has divested some non-core assets to cut its significant debt load and aims to cut its global workforce by more than 25% over the next two years, a clear path to growth is not visible. Estimates have gone up ahead of the company’s Q4 earnings release due to expected cost savings from the restructuring plan. Teva has a negative record of earnings surprises. “

Several other equities analysts also recently weighed in on TEVA. Goldman Sachs Group increased their price target on shares of Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the stock a buy rating in a report on Thursday, January 11th. Credit Suisse Group reissued an underperform rating and issued a $8.00 price target (down previously from $14.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, November 6th. Morgan Stanley raised shares of Teva Pharmaceutical Industries from an underweight rating to an equal weight rating and set a $18.00 price target on the stock in a research note on Friday, December 15th. Royal Bank of Canada set a $11.00 price objective on Teva Pharmaceutical Industries and gave the company a sell rating in a report on Wednesday, November 29th. Finally, Cantor Fitzgerald set a $10.00 price target on Teva Pharmaceutical Industries and gave the stock a hold rating in a report on Thursday, December 14th. Eight research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has an average rating of Hold and a consensus target price of $21.17.

Teva Pharmaceutical Industries (NYSE TEVA) traded down $0.07 during trading hours on Friday, reaching $22.00. 6,317,492 shares of the company were exchanged, compared to its average volume of 24,050,100. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $37.94. The stock has a market capitalization of $22,190.00, a price-to-earnings ratio of -3.75, a PEG ratio of 1.58 and a beta of 0.54. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, November 2nd. The company reported $0.95 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.03 by ($0.08). Teva Pharmaceutical Industries had a negative net margin of 24.35% and a positive return on equity of 15.70%. sell-side analysts predict that Teva Pharmaceutical Industries will post 3.72 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in TEVA. San Francisco Sentry Investment Group CA acquired a new position in Teva Pharmaceutical Industries during the second quarter worth $106,000. Penserra Capital Management LLC acquired a new position in Teva Pharmaceutical Industries during the third quarter worth $129,000. Fieldpoint Private Securities LLC acquired a new stake in Teva Pharmaceutical Industries in the third quarter valued at $171,000. Fayez Sarofim & Co. acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at $204,000. Finally, Chevy Chase Trust Holdings Inc. grew its holdings in Teva Pharmaceutical Industries by 81.5% in the third quarter. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company’s stock valued at $215,000 after purchasing an additional 5,497 shares during the last quarter. 51.96% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries (TEVA) Cut to Sell at Zacks Investment Research” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2018/01/16/teva-pharmaceutical-industries-teva-cut-to-sell-at-zacks-investment-research.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.